| Target Price | $37.23 |
| Price | $3.97 |
| Potential |
837.78%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target PAVmed, Inc. 2027 .
The average PAVmed, Inc. target price is $37.23.
This is
837.78%
register free of charge
$59.85
1,407.56%
register free of charge
$16.16
307.05%
register free of charge
|
|
| A rating was issued by 8 analysts: 7 Analysts recommend PAVmed, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the PAVmed, Inc. stock has an average upside potential 2027 of
837.78%
register free of charge
|
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.07 | 0.35 |
| 97.67% | 395.43% | |
| EBITDA Margin | -31,000.00% | -4,294.12% |
| 2,048.30% | 86.15% | |
| Net Margin | -5,385.71% | -5,790.53% |
| 605.38% | 7.52% |
4 Analysts have issued a sales forecast PAVmed, Inc. 2026 . The average PAVmed, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an PAVmed, Inc. EBITDA forecast 2026. The average PAVmed, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 PAVmed, Inc. Analysts have issued a net profit forecast 2026. The average PAVmed, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -5.63 | -3.20 |
| 138.35% | 43.16% | |
| P/E | negative | |
| EV/Sales | 123.33 |
4 Analysts have issued a PAVmed, Inc. forecast for earnings per share. The average PAVmed, Inc. EPS is
This results in the following potential growth metrics and future valuations:
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Ascendiant Capital |
Locked
➜
Locked
|
Locked | Aug 27 2026 |
| Ascendiant Capital |
Locked
➜
Locked
|
Locked | Jun 08 2026 |
| Ascendiant Capital |
Locked
➜
Locked
|
Locked | Apr 09 2026 |
| Ascendiant Capital |
Locked
➜
Locked
|
Locked | Dec 10 2025 |
| Ascendiant Capital |
Locked
➜
Locked
|
Locked | Oct 06 2025 |
| Ascendiant Capital |
Locked
➜
Locked
|
Locked | Jun 06 2025 |
| Ascendiant Capital |
Locked
➜
Locked
|
Locked | Apr 21 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Ascendiant Capital:
Locked
➜
Locked
|
Aug 27 2026 |
|
Locked
Ascendiant Capital:
Locked
➜
Locked
|
Jun 08 2026 |
|
Locked
Ascendiant Capital:
Locked
➜
Locked
|
Apr 09 2026 |
|
Locked
Ascendiant Capital:
Locked
➜
Locked
|
Dec 10 2025 |
|
Locked
Ascendiant Capital:
Locked
➜
Locked
|
Oct 06 2025 |
|
Locked
Ascendiant Capital:
Locked
➜
Locked
|
Jun 06 2025 |
|
Locked
Ascendiant Capital:
Locked
➜
Locked
|
Apr 21 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


